News
CLYM
8.65
-2.26%
-0.20
Climb Bio Price Target Announced at $18.00/Share by Mizuho
Dow Jones · 11h ago
Mizuho Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $18
Benzinga · 12h ago
Climb Bio initiated with an Outperform at Mizuho
TipRanks · 12h ago
CLIMB BIO INC <CLYM.O>: MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $18
Reuters · 13h ago
Weekly Report: what happened at CLYM last week (0406-0410)?
Weekly Report · 2d ago
Climb Bio announces annual shareholder meeting
Reuters · 5d ago
Climb Bio (CLYM) Gets a Buy from Piper Sandler
TipRanks · 5d ago
Climb Bio hosts R&D Spotlight webcast on budoprutug CD19 program opportunity
Reuters · 04/08 11:00
Climb Bio Price Target Maintained With a $8.00/Share by BTIG
Dow Jones · 04/08 09:49
BTIG Reiterates Buy on Climb Bio, Maintains $8 Price Target
Benzinga · 04/08 09:39
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Barchart · 04/08 06:00
BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
Reuters · 04/07 15:40
BUZZ-U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
Reuters · 04/07 13:08
BUZZ-Climb Bio rises as FDA grants fast-track status to kidney disease drug
Reuters · 04/07 11:48
Climb Bio granted Fast Track Designation to budoprutug by FDA
TipRanks · 04/07 11:28
Climb Bio Gets FDA Fast-Track Designation for Budoprutug in Rare Kidney Disease
Dow Jones · 04/07 11:24
Climb Bio says FDA grants Fast Track designation for budoprutug in pMN
Reuters · 04/07 11:04
CLIMB BIO INC - TO SHARE INITIAL PHASE 2 DATA IN SECOND HALF OF 2026
Reuters · 04/07 11:00
Weekly Report: what happened at CLYM last week (0330-0403)?
Weekly Report · 04/06 09:50
Climb Bio Consolidates Financial Leadership After SVP Departure
TipRanks · 04/03 20:33
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).